- REGENXBIO Announces Lancet Publication of Phase I/IIa Study Evaluating ABBV-RGX-314 as a One-Time Gene Therapy for Wet AMD
- REGENXBIO to Participate in Cantor Fitzgerald's Virtual DMD and Other Dystrophy Days
- REGENXBIO to Participate in Upcoming Investor Conferences
- REGENXBIO Announces Pricing of Upsized Public Offering of Common Stock and Pre-funded Warrants
- REGENXBIO Announces Proposed Public Offering of Common Stock
- REGENXBIO ANNOUNCES NEW POSITIVE INITIAL EFFICACY DATA FROM AFFINITY DUCHENNE® TRIAL
- REGENXBIO to Host Webcast Event to Discuss New Interim Clinical Data from the Phase I/II AFFINITY DUCHENNE® Trial
- REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- REGENXBIO to Host Conference Call on February 27 to Discuss Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
- REGENXBIO Announces Pivotal Trial of RGX-121 for the Treatment of MPS II Achieves Primary Endpoint
More ▼
Key statistics
As of last trade, Regenxbio Inc (RGNX:NSQ) traded at 15.94, 34.74% above the 52 week low of 11.83 set on Feb 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 15.67 |
---|---|
High | 16.28 |
Low | 15.52 |
Bid | 15.92 |
Offer | 15.96 |
Previous close | 15.64 |
Average volume | 459.94k |
---|---|
Shares outstanding | 49.04m |
Free float | 45.18m |
P/E (TTM) | -- |
Market cap | 767.03m USD |
EPS (TTM) | -6.03 USD |
Data delayed at least 15 minutes, as of Apr 23 2024 20:27 BST.
More ▼